On Demand Treatment of Reflux Disease
Information source: Norwegian University of Science and Technology
Information obtained from ClinicalTrials.gov on December 31, 2007
Link to the current ClinicalTrials.gov record.
Condition(s) targeted: Gastroesophageal Reflux
Intervention: Esomeprazole (Drug); Pectin-containing nature product (Drug)
Phase: Phase 4
Status: Completed
Sponsored by: Norwegian University of Science and Technology Official(s) and/or principal investigator(s):
Per G Farup, PhD, Study Chair, Affiliation: Norwegian University of Science and Technology
Summary
A comparison of the effect of on demand treatment with a pectin-containing natur product
(Aflurax) with that esomeprazole (Nexium)
Clinical Details
Official title: Aflurax Versus Nexium Given on Demand to Patients With Gastro-Esophageal Reflux Disease.
Study design: Treatment, Randomized, Open Label, Active Control, Single Group Assignment, Efficacy Study
Primary outcome: Symptomatic relief
Secondary outcome: Overall satisfaction
Detailed description:
A randomized, controlled, open trial comparing the symptomatic effect of a pectin-containing
procuct (Aflurax) with that of esomeprazole (Nexium 20 mg) given on-demand for 6 weeks.
Eligibility
Minimum age: 18 Years.
Maximum age: N/A.
Gender(s): Both.
Criteria:
Inclusion Criteria:
Mild and moderate reflux symptoms Age > 17 years Informed consent -
Exclusion Criteria:
Other conditions that might explain the symptoms Abuse of drugs or alcohol
-
Locations and Contacts
Sykehuset Innlandet HF, Gjøvik, Gjøvik 2819, Norway
Helse Nord-Trøndelag, Namsos, Norway
Helse Nord-Møre og Romsdal, Molde, Norway
Sykehuset Innlandet HF, Tynset, Tynset, Norway
Sykehuset Innlandet HF, Lillehammer, Lillehammer, Norway
Gjøvik Specialist Centre, Gjøvik 2800, Norway
Sykehuset Innlandet HF, Hamar, Hamar, Norway
Sykehuset Innlandet HF, Kongsvinger, Kongsvinger, Norway
Mosjøen sykehus, Mosjøen, Norway
Additional Information
Starting date: August 2002
Ending date: December 2004
Last updated: April 18, 2006
|
